Cobas

Molecular Diagnostics Market to be Worth $31.9 Billion by 2030: Grand View Research, Inc.

Retrieved on: 
Wednesday, July 5, 2023
Xpert, POC, Prevalence, NGS, COVID-19, Centrifugal micro-fluidic biochip, Infection, DSM-IV codes, USD, Microfluidics, Incidence, Acquisition, Miniaturization, Tuberculosis, Application, SAN, Roche, Cepheid variable, Cepheid (company), OTC, Diagnosis, Growth, Fungal infection, Power-on self-test, Cobas, PCR, Bloodstream infections, TMA, Pharmaceutical industry, Vaccine, Sequencing

The contraction in the market will be due to the decline in demand for molecular testing for COVID-19.

Key Points: 
  • The contraction in the market will be due to the decline in demand for molecular testing for COVID-19.
  • Read 270-page market research report, " Molecular Diagnostics Market Size, Share & Trends Analysis Report By Product (Instruments, Reagents), By Test Location, By Technology (PCR, Sequencing, INAAT, TMA), By Application, By Region, And Segment Forecasts, 2023 - 2030 ", published by Grand View Research.
  • Molecular diagnostics plays an important role in infectious disease testing as they can yield effective and fast results.
  • Such advances are anticipated to drive the global molecular diagnostics market.

Molecular Diagnostics Market to be Worth $31.9 Billion by 2030: Grand View Research, Inc.

Retrieved on: 
Wednesday, July 5, 2023
Xpert, POC, Prevalence, NGS, COVID-19, Centrifugal micro-fluidic biochip, Infection, DSM-IV codes, USD, Microfluidics, Incidence, Acquisition, Miniaturization, Tuberculosis, Application, SAN, Roche, Cepheid variable, Cepheid (company), OTC, Diagnosis, Growth, Fungal infection, Power-on self-test, Cobas, PCR, Bloodstream infections, TMA, Pharmaceutical industry, Vaccine, Sequencing

The contraction in the market will be due to the decline in demand for molecular testing for COVID-19.

Key Points: 
  • The contraction in the market will be due to the decline in demand for molecular testing for COVID-19.
  • Read 270-page market research report, " Molecular Diagnostics Market Size, Share & Trends Analysis Report By Product (Instruments, Reagents), By Test Location, By Technology (PCR, Sequencing, INAAT, TMA), By Application, By Region, And Segment Forecasts, 2023 - 2030 ", published by Grand View Research.
  • Molecular diagnostics plays an important role in infectious disease testing as they can yield effective and fast results.
  • Such advances are anticipated to drive the global molecular diagnostics market.

United States Molecular Diagnostics Market Analysis Report 2022: A $12.5 Billion Market by 2027 - Industry Trends, Growth, Insights, Impact of COVID-19, Company Analysis - ResearchAndMarkets.com

Retrieved on: 
Friday, November 25, 2022
Health, Biotechnology, COVID-19, Diagnosis, BioMérieux, Laboratory, Infection, Cell, Gene, United States national laboratories, Abbott Laboratories, Myriad Genetics, Roche Diagnostics, Projection, Patient, POC, Proteome, Government, Gen-Probe, NHS England, Ageing, Cancer, Genome, Protein, FISH, RNA transfection, PCR, Abbott, Power-on self-test, ID, Prognosis, Genetic testing, Death, CE, ISH, Research, Real-time polymerase chain reaction, Danaher Corporation, Cobas, Coronavirus, NHS, England, Investment, Pharmaceutical industry, Medical device, Medical imaging, Growth

The "United States Molecular Diagnostics Market, Size, Share, Forecast 2022-2027, Industry Trends, Growth, Insights, Impact of COVID-19, Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States Molecular Diagnostics Market, Size, Share, Forecast 2022-2027, Industry Trends, Growth, Insights, Impact of COVID-19, Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Molecular diagnostics has developed as a superior methodology in the United States over the previous decade, achieving the goal of speedier disease diagnosis with fewer complexities.
  • The COVID-19 outbreak is expected to boost the growth of the Molecular Diagnostics Market in the United States.
  • In the United States molecular diagnostics market in 2021, the infectious illness category held the most significant market share.

Roche granted FDA clearance for cobas pure integrated solutions for low- to mid-volume laboratories

Retrieved on: 
Monday, September 19, 2022
Laboratory, Immunoassay, FDA, Food, Disease, ISE, Health, Maintenance, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Automation, CEO, Technology, CE, Solution, Cardiology, Diagnosis, Calibration, RO, ROG, Decision-making, Infection, Ion-selective electrode, Fine chemical, Medical imaging, Medical device, Cobas

cobas pure integrated solutions brings together three diagnostic technologieson a single platform to optimize space and resources in low- to mid-volume laboratories.

Key Points: 
  • cobas pure integrated solutions brings together three diagnostic technologieson a single platform to optimize space and resources in low- to mid-volume laboratories.
  • The system also integrates seamlessly within health networks with cobas pro integrated solutions in their mid- to large-volume labs.
  • "The cobas pure integrated solutions marks a significant milestone in evolving standardization in lab diagnostics," said Matt Sause, president and CEO of Roche Diagnostics North America.
  • Furthermore, to ensure effective and efficient work within healthcare networks, the cobas pure system operates seamlessly with Roche's cobas pro integrated solutions for mid- to high-volume labs.

Oncology Molecular Diagnostics Global Market Research Report 2022: PCR, ISH, INNAT, Chips & Microarrays, Sequencing, Mass Spectroscopy, & TMA Analysis & Forecasts 2016-2021, 2021-2026F, 2031F - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 30, 2022
Genetics, Health, Oncology, Danaher Corporation, ICON plc, ISH, BD (company), EGFR, Breast cancer, Leica Biosystems, Cancer, Female, Immunohistochemistry, Polymerase chain reaction, Large-cell lung carcinoma, Hologic, Protein, Gen-Probe, Incidence, Cepheid variable, Blood, Beckman Coulter, Siemens Healthineers, Lung, American Cancer Society, Organization, Hospital, IHC, PCR, Saliva, FDA, Roche Diagnostics, Prostate, Mutation, ICON, Genomics, Acquisition, Growth, Health, TMA, Stanford University v. Roche Molecular Systems, Inc., Patient, Medical imaging, Cobas

Major players in the oncology molecular diagnostics market are Abbott Diagnostics, Becton Dickinson, Cepheid, Danaher Corporation, Beckman Coulter, Leica Biosystems, Gen-Probe (Hologic), Qiagen N.V., Roche Diagnostics, and Siemens Healthcare.

Key Points: 
  • Major players in the oncology molecular diagnostics market are Abbott Diagnostics, Becton Dickinson, Cepheid, Danaher Corporation, Beckman Coulter, Leica Biosystems, Gen-Probe (Hologic), Qiagen N.V., Roche Diagnostics, and Siemens Healthcare.
  • The high cost of molecular diagnostic tests is a key factor hampering the growth of the oncology molecular diagnostics market.
  • Therefore, the high cost of molecular diagnostic tests is expected to hamper the growth of the oncology molecular diagnostics market.
  • The countries covered in the oncology molecular diagnostics market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA.

Global Genotyping Market Analysis Report 2022: A $46.5 Billion Market by 2030 - Focus on PCR, Capillary Electrophoresis, Microarrays, Sequencing, & Mass Spectrometry - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 23, 2022
Health, Genetics, CAGR, Cobas, Therapy, Drug development, COVID-19, Medical Research Future Fund, Genomics, SNP, GT, Vaccine, Government, Bias, Thermo Fisher Scientific, Genotyping, Pharmacogenomics, Qiagen, Cancer, Research, Growth, USD, Mass spectrometry, Aquaculture, Roche, Alzheimer's disease, Partnership, Local government in Australia, Parkinson's disease, Lists of diseases, Patient, Application, Diagnosis, Genetic testing, Awareness, Center, COVID, PCR, Organization, Prevalence, Cervical cancer, NIH, Pharmaceutical industry, Animal, Fine chemical, Illumina, Color, Technology

Governments in multiple countries are taking various initiatives to provide support and funding to research organizations for personalized medicine, and genotyping research is anticipated to drive the market.

Key Points: 
  • Governments in multiple countries are taking various initiatives to provide support and funding to research organizations for personalized medicine, and genotyping research is anticipated to drive the market.
  • For instance, in August 2019, NIH funded USD 4.6 million initial grants to Color, a health technology company, for precision medicine initiatives and development.
  • Similarly, in 2018, the Government of Australia launched the Australian Genomics Health Futures Mission initiative.
  • North America accounted for the largest market share in 2021, owing to proactive government measures, high disease prevalence, technological advancements, and advanced healthcare infrastructure.

Lung Cancer Genomic Testing Markets, 2031 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 21, 2022
Health, Oncology, EGFR, CAGR, ROS, Cobas, FDA, Drug development, COVID-19, ALK, Polymerase chain reaction, FISH, LabCorp, Qiagen, IVD, Precision medicine, Efficiency, LDT, MET, Polymerase, Adoption, Research, Hospital, BIS, Growth, Takeda, Real-time polymerase chain reaction, Cdx, DNA sequencing, NGS, Investment, Roche, Quest Diagnostics, Thermo Fisher Scientific, Amgen, Partnership, Fluorescence in situ hybridization, Region, Lung cancer, Patient, KRAS, In situ hybridization, Diagnosis, Awareness, PCR, Organization, Large-cell lung carcinoma, Antibiotics, Medical imaging, Technology, Fluorescence, NSCLC

The growth in the global lung cancer genomic testing market is expected to be driven by increasing awareness and adoption of the lung cancer genomic testing market, recent launches of novel lung cancer genomic testing, and the expanding research in the field of lung cancer with an emphasis on pharmacogenomics and development of companion diagnostics.

Key Points: 
  • The growth in the global lung cancer genomic testing market is expected to be driven by increasing awareness and adoption of the lung cancer genomic testing market, recent launches of novel lung cancer genomic testing, and the expanding research in the field of lung cancer with an emphasis on pharmacogenomics and development of companion diagnostics.
  • Various companies are increasing investments in research and development to facilitate the development of lung cancer genomic testing, which is expected to further increase the adoption of lung cancer genomic tests.
  • Increasing recommendations by the international oncology societies for the use of genomic testing for lung cancer diagnosis provides major opportunities in the global lung cancer genomic testing market.
  • Since the lung cancer genomic testing is categorized under the elective procedure, the impact of the COVID-19 pandemic on the lung cancer genomic testing was negative.

World Molecular Diagnostics Market Analysis Report 2022-2030: The $31.9 Billion Market will Decline by 1.6% - ResearchAndMarkets.com

Retrieved on: 
Friday, June 17, 2022
Health, General Health, CAGR, Cobas, Cepheid variable, TMA, COVID-19, Microfluidics, Centrifugal micro-fluidic biochip, Tuberculosis, Bloodstream infections, GeneXpert MTB/RIF, Lists of diseases, Power-on self-test, POC, OTC, Growth, Infection, USD, X-Perts, Miniaturization, NGS, Roche Diagnostics, Acquisition, Incidence, Subclinical infection, Application, Diagnosis, Awareness, PCR, Prevalence, Medical device, Pharmaceutical industry, Vaccine, Medical imaging, Technology, Sequencing

The global molecular diagnostics market size is expected to reach USD 31.9 billion by 2030, and is expected to decline at a CAGR of -1.6% from 2022 to 2030.

Key Points: 
  • The global molecular diagnostics market size is expected to reach USD 31.9 billion by 2030, and is expected to decline at a CAGR of -1.6% from 2022 to 2030.
  • The contraction in the market will be due to the decline in demand for molecular testing for COVID-19.
  • However, factors such as the rising geriatric population and increasing demand for technologies such as NGS is expected to drive market growth.
  • Molecular diagnostics plays an important role in infectious disease testing as they can yield effective and fast results.

Global $9.56 Bn Oncology Molecular Diagnostics Markets, Analysis & Forecasts, 2015-2020, 2020-2025F, 2030F - ResearchAndMarkets.com

Retrieved on: 
Monday, December 13, 2021
Health, Oncology, American Cancer Society, Leica Biosystems, Organization, Roche Diagnostics, Gen-Probe, FDA, Protein, Genomics, Cancer, Stanford University v. Roche Molecular Systems, Inc., Growth, Technology, Incidence, EGFR, COVID-19, Female, Breast cancer, Beckman Coulter, Saliva, Lung, Prostate, Siemens Healthineers, BD (company), Patient, Danaher Corporation, Mutation, Blood, Cepheid variable, Hologic, Health, Large-cell lung carcinoma, Medical imaging, Cobas

The high cost of molecular diagnostic tests is a key factor hampering the growth of the oncology molecular diagnostics market.

Key Points: 
  • The high cost of molecular diagnostic tests is a key factor hampering the growth of the oncology molecular diagnostics market.
  • Therefore, the high cost of molecular diagnostic tests is expected to hamper the growth of the oncology molecular diagnostics market.
  • Global Oncology Molecular Diagnostics Market, Segmentation by Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
    6.2.
  • Global Oncology Molecular Diagnostics Market, Segmentation by Technology, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

Roche launches the first infectious disease tests and cobas omni Utility Channel for use on the cobas 5800 System in countries accepting the CE Mark

Retrieved on: 
Wednesday, December 15, 2021
DJSI, Roche Diagnostics, Hoffmann-La Roche, RNA, Genentech, PCR, Molecule, HIV-1, Essential medicines, Severe acute respiratory syndrome coronavirus 2, LDT, Diagnosis, Utility, Automation, Genome, Stanford University v. Roche Molecular Systems, Inc., World, IVD, LIS, Time, HIV, Plasma, Serum, Dow Jones, RO, Dried blood spot, Patient, HBV, Infection, Laboratory, CE, Joint Medical Service (Germany), HIV-2, Cobas, Ophthalmology, HCV, Central nervous system, CHF, ROG, Fine chemical, Medical imaging, Vaccine, Chugai Pharmaceutical Co., System

The cobas 5800 System will offer the same menu as the cobas 6800 and 8800 Systems.

Key Points: 
  • The cobas 5800 System will offer the same menu as the cobas 6800 and 8800 Systems.
  • Roche is pursuing CE approval for continued menu expansion on the cobas 5800 System, including cobas SARS-CoV-2, through early-to-mid 2022.
  • Roche anticipates tests to be available beyond CE markets in additional countries in 2022.
  • The cobas omni Utility Channel on the cobas 5800 System enables a broader testing menu by consolidating open channel assays with Roche in vitro diagnostic (IVD) assays on a single platform.